Madrigal Pharmaceuticals, Inc. (MDGL)
499.40
-0.31
(-0.06%)
USD |
NASDAQ |
Oct 02, 16:00
499.58
+0.18
(+0.04%)
Pre-Market: 20:00
Madrigal Pharmaceuticals EPS Diluted (Quarterly) : -1.988 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.988 |
| March 31, 2026 | -3.251 |
| December 31, 2025 | -2.566 |
| September 30, 2025 | -5.079 |
| June 30, 2025 | -1.904 |
| March 31, 2025 | -3.315 |
| December 31, 2024 | -2.709 |
| September 30, 2024 | -4.919 |
| June 30, 2024 | -7.101 |
| March 31, 2024 | -7.376 |
| December 31, 2023 | -5.678 |
| September 30, 2023 | -5.344 |
| June 30, 2023 | -4.686 |
| March 31, 2023 | -4.228 |
| December 31, 2022 | -4.984 |
| September 30, 2022 | -4.747 |
| June 30, 2022 | -4.135 |
| March 31, 2022 | -3.363 |
| December 31, 2021 | -3.780 |
| September 30, 2021 | -3.792 |
| June 30, 2021 | -3.720 |
| March 31, 2021 | -3.317 |
| December 31, 2020 | -3.820 |
| September 30, 2020 | -3.752 |
| June 30, 2020 | -3.176 |
| Date | Value |
|---|---|
| March 31, 2020 | -2.342 |
| December 31, 2019 | -1.798 |
| September 30, 2019 | -1.390 |
| June 30, 2019 | -1.282 |
| March 31, 2019 | -0.9815 |
| December 31, 2018 | -0.7476 |
| September 30, 2018 | -0.556 |
| June 30, 2018 | -0.45 |
| March 31, 2018 | -0.4505 |
| December 31, 2017 | -0.67 |
| September 30, 2017 | -0.68 |
| June 30, 2017 | -0.69 |
| March 31, 2017 | -0.50 |
| December 31, 2016 | -0.6484 |
| September 30, 2016 | -1.34 |
| June 30, 2016 | -571.55 |
| March 31, 2016 | -340.20 |
| December 31, 2015 | -374.08 |
| September 30, 2015 | -8.75 |
| June 30, 2015 | -5.25 |
| March 31, 2015 | -6.65 |
| December 31, 2014 | -6.65 |
| September 30, 2014 | -6.65 |
| June 30, 2014 | -8.40 |
| March 31, 2014 | -9.80 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Exelixis, Inc. | 0.8166 |
| Insmed, Inc. | -0.0609 |
| United Therapeutics Corp. | 7.271 |
| Karyopharm Therapeutics, Inc. | -2.316 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -57.94M |
| Revenue (Quarterly) | 364.25M |
| Total Expenses (Quarterly) | 422.19M |
| Enterprise Value | 11.04B |
| Gross Profit Margin (Quarterly) | 88.91% |
| Profit Margin (Quarterly) | -15.91% |
| Earnings Yield | -2.58% |
| Normalized Earnings Yield | -2.563 |